GMAB · Genmab A/S
$44.69
+2.04% last session
End-of-day data · close of 2026-10-26
Market cap
$27B
Enterprise value
$30B
Trailing P/E
34.9
Forward P/E
29.3
Dividend yield
0.0%
Beta
0.64
Avg volume
3M
Employees
3K
Daily Change %
2.04%
5 Days Change
11.71%
10 Days Change
20.77%
30 Days Change
26.51%
60 Days Change
34.47%
Month to Day Change
29.33%
Year to Day Change
45.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GMAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-26
Latest call per bank · past 12 months
JP Morgan
Overweight$0.00
-100.0% vs priceWells Fargo
Overweight$40.00
-10.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-26 | TD Cowen | Maintains | Buy | $43.00 → $52.00 |
| 2026-10-26 | JP Morgan | Upgrade | Neutral → Overweight | $0.00 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $40.00 → $45.00 |
| 2026-10-07 | Guggenheim | Maintains | Buy | $54.00 → $58.00 |
| 2026-10-07 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $50.00 |
| 2026-10-05 | Guggenheim | Maintains | Buy | $45.00 → $54.00 |
| 2026-09-14 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-08-07 | Guggenheim | Maintains | Buy | $40.00 → $42.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- bearish: RSI (14): RSI is 80 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 26.0% above the 50-day MA ($35.47).
- bullish: Price vs 200-day MA: Trading 48.4% above the 200-day MA ($30.11).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.64) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($44.69).
GMAB Price Chart
Loading chart for GMAB…
Fundamentals
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.